Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trastuzumab deruxtecan has good activity in advanced HER2-positive breast cancer

Publish date:: December 12, 2019

Key clinical point: Trastuzumab linked to a toxic topoisomerase payload was effective in patients with a median six prior lines of therapy.

Major finding: The overall response rate was 60.9%.

Study details: An open-label, phase 2 study in 184 patients with HER2-positive metastatic breast cancer treated at the 5.4-mg/kg dose level.

Disclosures: The study was funded by Daiichi Sankyo and AstraZeneca. Dr. Krop disclosed consulting fees, honoraria from each company, and research support from Genentech/Roche and Pfizer.

Citation:

Krop I et al. SABCS 2019, Abstract GS1-03.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,